Phase I trial and pharmacokinetic study of sorafenib in children with neurofibromatosis type I and plexiform neurofibromas
Pediatric Blood & Cancer2012Vol. 60(3), pp. 396–401
Citations Over TimeTop 10% of 2012 papers
AeRang Kim, Eva Dombi, Kathleen Tepas, Elizabeth Fox, Staci Martin, Pamela L. Wolters, Frank M. Balis, Nalini Jayaprakash, Barış Türkbey, Naira Muradyan, Peter L. Choyke, Alyssa Reddy, Bruce R. Korf, Brigitte C. Widemann
Abstract
Children with NF1 and PN did not tolerate sorafenib at doses substantially lower than the MTD in children and adults with malignant solid tumors. Future trials with targeted agents for children with NF1 may require a more conservative starting dose and separate definitions of dose limiting toxicities (DLT) than children with cancer.
Related Papers
- → Combining Sorafenib and Immunosuppression in Liver Transplant Recipients with Hepatocellular Carcinoma(2021)11 cited
- → Selection of Patients with Hepatocellular Carcinoma for Sorafenib(2009)36 cited
- The up-regulation of P62 levels is associated with resistance of sorafenib in hepatocarcinoma cells.(2019)
- Long-lasting tumour response to sorafenib therapy in advanced hepatocellular carcinoma.(2014)
- → Μελέτη της επιδράσεως του αντιαγγειογενετικού παράγοντα sorafenib στην ηπατική αναγέννηση(2015)